Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) in advanced dedifferentiated liposarcoma. Additional presentations cover investigational therapies like an antibody-drug conjugate targeting Nectin-4 and Kelonia Therapeutics' in vivo CAR-T therapy for multiple myeloma. These findings highlight Lilly's expanding oncology portfolio and ongoing commitment to innovative cancer treatments. The data presentations are expected to influence future cancer treatment approaches and regulatory decisions.
President Trump highlighted the creation of over 2,600 manufacturing jobs in Pennsylvania during a visit to the Mack Trucks facility. He credited his administration's policies, including rolling back stringent fuel emissions regulations, for boosting...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. Th...
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38 per share plus potential milestone payments, valuing the deal at about $7.8 billion. The transaction will close on June 24, 2026, ...
